Pharmacoeconomic analysis of using biological agents in the treatment of rheumatoid arthritis
By taking into account the fact that there are a few alternative biological agents for the treatment of rheumatoid arthritis (RA), the cost of an annual therapy cycle using the agents is greater than that of high-technology surgical interventions, and a pharmacoeconomic study substantiating the opti...
Main Authors: | I. I. Dyakov, D. V. Goryachev |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2014-09-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/566 |
Similar Items
-
Pharmacoeconomic evaluation of costs of rheumatoid arthritis therapy with selected biological treatment
by: Krzysztof Kowalik, et al.
Published: (2018-12-01) -
Pharmacoeconomic analysis of subdermal tocilizumab in patients with rheumatoid arthritis
by: S. K. Zyryanov, et al.
Published: (2018-05-01) -
Biological agents in rheumatoid arthritis
by: Shankar S, et al.
Published: (2004-10-01) -
Determination of recombinant biological agents requirement for patients with rheumatoid arthritis: development of standardized indications for prescription
by: M Y Telnyh, et al.
Published: (2009-12-01) -
Safety of using genetic engineering biological agents in rheumatoid arthritis
by: N V Chichasova, et al.
Published: (2010-03-01)